I'd just like to say that we'd also like to see a range of therapeutic products available to people with Parkinson's, because there are some decisions made where there's only one in a class, and another product that would come forward, that would be beneficial to individuals who might not respond to that one particular drug, the individuals cannot get.
There needs to be a view to having more therapeutic options available so that clinicians can have an opportunity to look for the best fit in terms of pharmacological intervention that works best for the individual.